Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

eading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), Type 2 diabetes, ulcerative colitis, glioma and schizophrenia. For further information, please visit www.gwpharm.com.

Forward-looking statements

This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding our clinical goals, our plans for a clinical trial, the ability to conduct clinical trials sufficient to achieve positive completion, and the therapeutic and commercial value of the company's compounds. To the degree we are able to conduct clinical trials, we may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Forward-looking statements involve risks and uncertainties.  Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex® and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including the prospectus related to the NASDAQ offering filed by GW with the SEC on May 1, 2013. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result o
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly ... this time period, doctors did not know that they needed ... death of vulnerable patients. In the same way, medical interns ... unwittingly transmitting herpes viruses to their patients. The CBCD explains. ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that ... trial sites by the end of the quarter, with ... now open and active where patients can enroll in ... for Glioblastoma multiforme (GBM), the most lethal form of ...
... ProteinSimple today announced the launch of the iCE3, ... protein-based therapeutics. The iCE3 platform will be unveiled ... 2011, at Amelia Island, FL. Manufacturers ... Imaged capillary electrophoresis (iCE) systems detect subtle impurities ...
... 63 unique dust particles from their laboratory and that,s ... new kind of sensor when dust got stuck inside it, ... single dust particles. In a recent issue of The ... the discovery could aid the study respiratory diseases caused by ...
Cached Biology Technology:NORTHWEST BIO Announces Positive Third Quarter Progress 2NORTHWEST BIO Announces Positive Third Quarter Progress 3NORTHWEST BIO Announces Positive Third Quarter Progress 4ProteinSimple Launches New System for Protein Biologics 21 room -- 63 different dust particles? Researchers aim to build dust library 21 room -- 63 different dust particles? Researchers aim to build dust library 3
(Date:4/22/2014)... research projects study the effects of temperature and precipitation ... However, an important component of climate research, the UV-B ... in collaboration with their colleagues from the Universities in ... from the U.S. NASA space agency in such a ... influence of UV-B radiation on organisms. , The basic ...
(Date:4/22/2014)... not only on weight loss but also on diabetes ... University of Cincinnati have shown that the health benefits ... size but by increased levels of bile acids in ... indicate that bile acids could be a new target ... the Sahlgrenska Academy has demonstrated that obesity surgery is ...
(Date:4/21/2014)... that can one day be applied to medical and ... Nguyen has been recognized as one of the nation,s ... physics, Nguyen is among the 2014 recipients of the ... most prestigious awards available to undergraduate students, the Goldwater ... in mathematics, the natural sciences or engineering with plans ...
Breaking Biology News(10 mins):UV-radiation data to help ecological research 2Researchers identify a mechanism linking bariatric surgery to health benefits 2UH student named Goldwater Scholar, 2 more receive honorable mention 2UH student named Goldwater Scholar, 2 more receive honorable mention 3UH student named Goldwater Scholar, 2 more receive honorable mention 4
... published online this week in the open access journal PLoS ... resolution genetic map for the mouse genome--one of the most ... , To create this map, they used two groups ... the other of recombinant inbred lines (RI). Using the single ...
... GB Virus type C (GBV-C) protects against HIV infection is ... (VA) Iowa City Health Care System and the University of ... from growing in cell models. , The team found that ... NS5A greatly slows down HIV from replicating in cells grown ...
... determine the sequence of nucleotide bases in the 6-billion-base-pair ... UC San Diego and eight other universities and biotech ... the cost to only $1,000 per human genome sequenced. ... to understanding and routinely treating hundreds of inherited diseases, ...
Cached Biology News:Mapping the mouse genome 2Study IDs protein that inhibits HIV from growing in cell cultures 2Study IDs protein that inhibits HIV from growing in cell cultures 3Scientists win grants to develop $1,000 genome sequencing technology 2
... The Varian Cary 50 ... reduces your cost per analysis ... throughput of the award-winning Cary ... analyze up to 384 samples ...
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 400 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: